Cephalon Finalizes $425M Deal Over Off-Label Claims
Cephalon Inc. has finalized a $425 million settlement with the federal government to end allegations by company sales representatives and others that it marketed three of its drugs for uses that...To view the full article, register now.
Already a subscriber? Click here to view full article